Gilead Sciences
Key Metrics
How this company measures up on the fundamentals that matter
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $131 against a fair value of $192, a 32% discount. Strong competitive moat. Fails ethical screen (Debt ratio). Ranks better than 82% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | MERCIER JOHANNA | Officer | 25,000 | $1,666,000 | |
| 2026-05-15 | MERCIER JOHANNA | Officer | 28,000 | $3,676,199 | |
| 2026-05-15 | DICKINSON ANDREW D | Chief Financial Officer | 3,000 | $396,810 | |
| 2026-04-30 | RODRIGUEZ JAVIER | Director | 1,146 | — | |
| 2026-04-30 | HORNING SANDRA | Director | 1,146 | — | |
| 2026-04-30 | LOVE TED WENDELL | Director | 1,146 | — | |
| 2026-04-30 | BLUESTONE JEFFREY | Director | 1,146 | — | |
| 2026-04-30 | MANWANI HARISH | Director | 1,146 | — | |
| 2026-04-30 | BARTON JACQUELINE K | Director | 1,146 | — | |
| 2026-04-30 | WELTERS ANTHONY | Director | 1,146 | — |
Political Trading Activity
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 6 May2026 | Jared Moskowitz | Democrat | buy | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 15K–50K |
| 15 May2026 | Ro Khanna | Democrat | buy | 15K–50K |
What If You'd Bought GILD?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $133.52 | -8.7% | — | $913 | -8.7% |
| 2 Months | $138.99 | -12.3% | — | $877 | -12.3% |
| 3 Months | $144.39 | -15.6% | $0.82 | $850 | -15.0% |
| 6 Months | $121.71 | +0.1% | $1.61 | $1,014 | +1.4% |
| 1 Year | $107.24 | +13.6% | $3.19 | $1,166 | +16.6% |
| 2 Years | $61.26 | +98.9% | $6.29 | $2,092 | +109.2% |
| 3 Years | $70.57 | +72.7% | $9.31 | $1,859 | +85.9% |
| 5 Years | $57.08 | +113.5% | $15.11 | $2,399 | +139.9% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Latest Analysis — GILD
Timestamped intelligence from our daily research pipeline
12 June 2026 • Alpha Insights Sector Research Top 50 Healthcare Stocks Ranked: Pharma, Biotech, and MedTech Scored for Quality and Ethics Healthcare has become the quiet defensive rotation of...
NFP Prints at 08:30 ET. Here Is What Thursday Delivered and Every Outcome Asia Needs to Model Before It Happens. NFP Prints at 08:30 ET. Here Is What Thursday Delivered...
Tech Rescued the ATH, Crude Surrendered the Gulf Spike, and Tomorrow NFP Decides Everything Tech Rescued the ATH, Crude Surrendered the Gulf Spike, and Tomorrow NFP Decides Everything Post-Close |...
London Held Its Nerve. Now New York Walks Into NFP Eve With Gunfire in the Gulf and Earnings at the Bell. Pre-NY Brief | Thursday 8 May 2026 | 13:00...
Gunfire in the Gulf, NFP in 24 Hours: London Opens Into the Most Complicated Setup of the Week. Pre-London Brief | Friday 8 May 2026 | 06:30 GMT | 01:30...
Seventeen Layers Said the Same Thing: This Market Is Holding Its Breath Until 08:30 Friday. 8 May 2026 | Alpha Insights | Overwatch This is the analysis. Seventeen posts. Four...
The ATH Pulled Back, the Gulf Reignited, and Breadth Cracked Further. Three Stories the Tape Told on Thursday. 8 May 2026 | Alpha Insights | Market Moves Every session tells...
Thursday After-Close Could Rewrite the AI Infrastructure Thesis. Here Is What Wednesday’s Results Told You First. 8 May 2026 | Alpha Insights | Earnings Echo Wednesday’s earnings reports delivered a...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31